Cancer Immunotherapy: Combinations
Organizer(s): Chris Boshoff, Lieping Chen and Lisa CoussensDate: March 23 - 27, 2018
Location: Fairmont The Queen Elizabeth, Montreal, QC, Canada
By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This conference helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: 1) Elucidate rational combinations for immunotherapy; 2) Discuss preclinical and other models to inform combinatorial approaches; 3) Understand the relevance for biomarker approaches; and 4) Provide insights into the latest preclinical and clinical data for immunotherapy combinations.
Scholarship Deadline: November 21 2017
Discounted Abstract Deadline: November 21 2017
Abstract Deadline: December 19 2017
Discounted Registration Deadline: January 16 2018
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1 R13 CA224868-01
Funding for this conference was made possible (in part) by 1 R13 CA224868-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.